Published in Pharma Law Weekly, July 14th, 2009
"This study describes the susceptibility to second-and third-line antituberculosis drugs among MDRTB cases and treatment outcome of identified XDRTB cases. The results of second-line antituberculosis drug susceptibility tests in the UK between January 1995 and December 2007 were retrospectively reviewed and clinicians contacted for treatment outcome of XDRTB cases. included all 678 patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.